Viridian Therapeutics, Inc. (NASDAQ:VRDN) Holdings Decreased by Vivo Capital LLC

Vivo Capital LLC cut its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 41.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 982,576 shares of the company's stock after selling 695,631 shares during the period. Viridian Therapeutics accounts for 2.1% of Vivo Capital LLC's investment portfolio, making the stock its 9th biggest position. Vivo Capital LLC owned approximately 1.24% of Viridian Therapeutics worth $18,836,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of the business. FMR LLC grew its stake in Viridian Therapeutics by 6.2% during the fourth quarter. FMR LLC now owns 11,881,912 shares of the company's stock valued at $227,776,000 after acquiring an additional 698,434 shares in the last quarter. Vanguard Group Inc. grew its position in Viridian Therapeutics by 4.0% during the fourth quarter. Vanguard Group Inc. now owns 4,595,049 shares of the company's stock worth $88,087,000 after buying an additional 174,952 shares in the last quarter. Alliancebernstein L.P. increased its stake in Viridian Therapeutics by 3.8% in the 4th quarter. Alliancebernstein L.P. now owns 2,286,994 shares of the company's stock worth $43,842,000 after acquiring an additional 84,255 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Viridian Therapeutics by 11.1% in the 4th quarter. Geode Capital Management LLC now owns 1,658,980 shares of the company's stock valued at $31,809,000 after acquiring an additional 165,669 shares in the last quarter. Finally, Loomis Sayles & Co. L P bought a new stake in shares of Viridian Therapeutics during the 4th quarter valued at about $26,845,000.

Analysts Set New Price Targets

Several research firms recently weighed in on VRDN. HC Wainwright restated a "buy" rating and issued a $34.00 price objective on shares of Viridian Therapeutics in a research report on Wednesday. Needham & Company LLC reissued a "buy" rating and issued a $38.00 price target on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Three equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $35.70.

Viridian Therapeutics Trading Down 0.4 %

Viridian Therapeutics stock traded down $0.06 during mid-day trading on Friday, hitting $13.50. The company's stock had a trading volume of 524,676 shares, compared to its average volume of 1,200,464. Viridian Therapeutics, Inc. has a 12 month low of $9.90 and a 12 month high of $27.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The business has a 50 day moving average price of $14.24 and a 200-day moving average price of $18.27. The stock has a market cap of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 0.81.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($1.05) by $0.24. The firm had revenue of $0.07 million during the quarter, compared to the consensus estimate of $0.05 million. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. As a group, analysts forecast that Viridian Therapeutics, Inc. will post -4.03 EPS for the current year.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.